Skip to main content
PAS 2024 Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Pre-Conference Ticketed Event
Pre-Conference Ticketed Event
APA Award Winner
APA Award Winner
APS Award Winner
APS Award Winner
ASPN Award Winner
ASPN Award Winner
SPR Award Winner
SPR Award Winner
On Demand Presentation
On Demand Presentation
Poster Icons
SPR Award Winner
SPR Award Winner
Back
Evaluation ViewAttendees 40
Hot Topic Symposia

Academic and Research Skills

Clinical Research

Critical Care

Endocrinology

General Pediatrics

Genomics/Epigenomics

Neonatology
Session Type: Hot Topic Symposia

Transient and Persistent Neonatal Hyperglycemia: Mechanisms and Therapeutic Options

Monday, May 6, 2024
8:00 AM – 9:30 AM ET
Location: Metro Toronto Convention Centre: 718 A
CE: Live CME: 1.5

Selected By: Endo
Co-sponsored By: Neonatal
Disclosure(s):
Sara E. Pinney, MD, MS: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Alfonso Galderisi, MD PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Session

Description: 1.

Introduction: Sara Pinneys (USA) and Alfonso Galderisi (USA) will introduce the speakers (5-min).
2. Diagnostic challenges of neonatal hyperglycemia. (20-min)
Michel Polak (France) will discuss the diagnostic pathway for neonatal hyperglycemia in preterm and term infants including the characteristics of monogenic diabetes with neonatal onset and other causes of transient or persistent neonatal hyperglycemia. Current guidelines will be reviewed. (20-min)
3.Therapeutic options for neonatal hyperglycemia: when to treat and how to treat? (20-min)
Elsa Kermorvant will present the pros and cons of early insulin treatment of neonatal hyperglycemia and the preliminary results of the French GALOP trial (oral glybenclamide for neonatal hyperglycemia in preterm infants). The use of sulfonylureas as first line treatment not only for some forms of neonatal monogenic diabetes but also for transient neonatal hyperglycemia of preterm infants will be explored.
4. Evidence from the bench:hyperglycemia and neonatal brain (15-min)
Marianne Berdugo will present experimental evidence on the effect of neonatal hyperglycemia and sulfonylureas treatment on retinal and brain development in rats.
5.Evidence from the clinic:hyperglycemia and neonatal brain (15-min)
Siri Greeley will provide an overview of the effect of neonatal hyperglycemia on long term neurodevelopment, including data from longitudinal cohorts of infants with monogenic neonatal diabetes treated with sulfonylureas.
6. Q&A: 15-min

Learning Objectives:

  • Upon completion, participants will be able to run a diagnostic algorithm for neonatal hyperglycemia
  • Upon completion, participants will be able to manage neonatal hyperglycemia due to monogenic causes
  • Upon completion, participants will be able to discuss current challenges of neonatal hyperglycemia treatment

Presentations:

  • 8:00 AM – 8:20 AM ET
    Diagnostic challenges of neonatal hyperglycemia : genetics and non-genetic causes

    Speaker: Michel Polak, MD, PhD (he/him/his) – Université Paris Cité, Hôpital Necker Enfants Malades

  • 8:20 AM – 8:40 AM ET
    Therapeutic options for neonatal hyperglycemia : when to treat and how to treat

    Speaker: Elsa Kermorvant, MD, PhD (she/her/hers) – Université Paris Cité, Hôpital Necker-Enfants malades

  • 8:40 AM – 9:00 AM ET
    Evidence from the bench: hyperglycemia and neonatal neuroretina

    Speaker: Marianne Berdugo, DVM, PhD (she/her/hers) – Université Paris Cité - INSERM 1138

  • 9:00 AM – 9:20 AM ET
    Evidence from the clinic: Hyperglycemia and neonatal brain : why to treat - a clinical perspective

    Speaker: Siri Atma Greeley, MD, PhD (he/him/his) – University of Chicago

    Speaker: Sarbattama Sen, MD (she/her/hers) – Women and Infants' Hospital of Rhode Island